Loading organizations...
Device of Tomorrow Capital operates as an early-stage investment fund, exclusively focused on the medical technology sector. The firm identifies and supports breakthrough innovations within MedTech, providing capital and strategic guidance. Its approach empowers emerging companies developing novel medical devices and digital health solutions to address pressing healthcare challenges.
Henry Yan, a Managing Partner, founded Device of Tomorrow Capital. His establishment arose from a keen understanding of significant opportunities and unmet needs within the dynamic medical technology landscape. Yan’s insight led to creating a specialized investment vehicle designed to propel MedTech ventures from early stages toward market entry.
The firm's primary clientele are early-stage MedTech startups and innovators seeking financial backing and strategic collaboration. Device of Tomorrow Capital envisions accelerating the development and adoption of transformative medical technologies. Its mission is to be a critical catalyst in bringing forth advanced healthcare solutions that enhance global patient care and improve health outcomes.
Device of Tomorrow Capital has 3 tracked investments across 3 companies. The latest tracked deal is $2.3M Seed in CARI Health in January 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 10, 2023 | CARI Health | $2.3M Seed | Mysty Rusk | Chemical Angel Fund, Cove Fund, NuFund Venture Group |
| Jan 10, 2023 | Telesair | $22.0M Series A | Charles Huang | Berkeley Catalyst Fund, Patrick Hogan, ShangBay Capital, Ultrastar Ventures |
| Jun 23, 2020 | Carlsmed | $2.5M Seed | Mike Benvenuti | Wavemaker Three Sixty Health |
